Imatinib

• Description :

  Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively[1][2][3][4]. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV[5].

• Product Name Alternative :

  STI571; CGP-57148B

• UNSPSC :

  12352005

• Hazard Statement :

  H361

• Target :

  Autophagy; Bcr-Abl; c-Kit; PDGFR; SARS-CoV

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; Autophagy; Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Imatinib.html

• Concentration :

  10mM

• Purity :

  99.95

• Solubility :

  DMSO : 12.5 mg/mL (ultrasonic)

• Smiles :

  CN(CC1)CCN1CC2=CC=C(C(NC3=CC=C(C)C(NC4=NC(C5=CC=CN=C5)=CC=N4)=C3)=O)C=C2

• Molecular Formula :

  C29H31N7O

• Molecular Weight :

  493.60

• Precautions :

  H361

• References & Citations :

  [1]Heinrich MC, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000 Aug 1;96 (3) :925-32.|[2]Guida T, et al. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res. 2007 Jun 1;13 (11) :3363-9.|[3]Iqbal N, et al. Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:357027.|[4]Okuda K, et al. ARG tyrosine kinase activity is inhibited by STI571.Blood. 2001 Apr 15;97 (8) :2440-8|[5]Yao JC, et al. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 2007 Jan 1;13 (1) :234-40.|[6]Sun XC, et al. Depletion of telomerase RNA inhibits growth of gastrointestinal tumors transplanted in mice. World J Gastroenterol. 2013 Apr 21;19 (15) :2340-7.|[7]Yildiz C, et al. Effect of imatinib on growth of experimental endometriosis in rats. Eur J Obstet Gynecol Reprod Biol. 2016 Feb;197:159-63.|[8]Jeanne M Sisk, et al. Coronavirus S Protein-Induced Fusion Is Blocked Prior to Hemifusion by Abl Kinase Inhibitors. J Gen Virol. 2018 May;99 (5) :619-630.|[9]Coleman CM, et al, Frieman MB. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion. J Virol. 2016;90 (19) :8924‐8933. Published 2016 Sep 12.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Citation 01 :

  ACS Appl Mater Interfaces. 2025 Jan 15;17 (2) :2884-2898.|Acta Pharmacol Sin. 2023 May;44 (5) :984-998.|Arch Pharm (Weinheim) . 2022 Oct 10; e2200367.|Bioanalysis. 2018 Jul;10 (14) :1099-1113.|Biochem Biophys Res Commun. 2025 May 15:771:152027.|Biochem Pharmacol. 2023 Mar:209:115442.|Bioengineering (Basel) . 2025 Oct 19;12 (10) :1121.|Biomed Pharmacother. 2024 Jan:170:115778.|Biomed Pharmacother. 2025 Jun 20:189:118246.|Biomolecules. 2022 Jun 11;12 (6) :819.|bioRxiv. 2024 Dec 20:2024.12.19.629301.|bioRxiv. 2024 June 09.|bioRxiv. 2025 February 26.|bioRxiv. 2025 Jul 12:2025.07.08.663754.|bioRxiv. 2025 Jun 13:2025.06.13.659082.|bioRxiv. 2025 Sep 30.|Blood Vessel Thromb Hemost. 2025 Nov 17.|Breast Cancer Res Treat. 2025 Jun;211 (2) :467-478.|Cancer Biol Ther. 2019;20 (6) :877-885.|Cancer Commun (Lond) . 2025 Nov 10.|Cancer Lett. 2019 Apr 10:447:105-114.|Cancer Med. 2019 Sep;8 (11) :5352-5366.|Cancer Res. 2025 Jan 2;85 (1) :101-117.|Cell Biosci. 2020 Feb 12;10:16.|Cell Biosci. 2024 Jun 29;14 (1) :87.|Cell Chem Biol. 2018 Aug 16;25 (8) :996-1005.e4.|Cell Death Dis. 2022 Apr 20;13 (4) :384.|Cell Metab. 2022 Mar 1;34 (3) :424-440.e7.|Cell Rep Med. 2025 Apr 2:102053.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Clin Cancer Res. 2020 Aug 15;26 (16) :4349-4359.|Clin Chem. 2019 Dec;65 (12) :1522-1531. |Clin Sci. 2021 Jul 30;135 (14) :1751-1765.|Clin Transl Med. 2025 Feb;15 (2) :e70231.|Commun Biol. 2024 Jul 10;7 (1) :843.|Curr Res Toxicol. 2024 Jul 14:7:100187.|Drug Des Devel Ther. 2022 Aug 4;16:2545-2557.|Ecotoxicol Environ Saf. 2025 Nov 15:307:119433.|EMBO J. 2025 Nov 3.|EMBO Mol Med. 2021 Apr 9;13 (4) :e13144.|Eur J Pharmacol. 2021 Apr 15:897:173944.|Eur J Pharmacol. 2021 Dec 15:913:174633.|Eur J Pharmacol. 2021 Sep 5:906:174217.|Exp Hematol Oncol. 2024 Dec 18;13 (1) :121.|Gastric Cancer. 2023 Sep;26 (5) :677-690.|Heliyon. 2024 Aug 22;10 (16) :e36640.|Hum Cell. 2025 Jan 3;38 (2) :38.|In Vivo. 2024 Sep-Oct;38 (5) :2310-2317.|Inflamm Regen. 2022 Sep 26;42 (1) :44.|Int J Mol Sci. 2023 Feb 2;24 (3) :2849.|J Biomed Inform. 2023 Jun:142:104383.|J Cell Biochem. 2023 Sep;124 (9) :1404-1422.|J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Apr 15:1237:124100.|J Med Chem. 2016 Sep 22;59 (18) :8456-72. |J Med Chem. 2019 Jul 11;62 (13) :6083-6101.|J Med Chem. 2019 May 23;62 (10) :5006-5024. |J Med Chem. 2021 Mar 11;64 (5) :2725-2738.|J Tradit Complement Med. 2023 Nov 22;14 (3) :321-334.|J Transl Med. 2024 Dec 20;22 (1) :1119.|Med Sci Monit. 2017 Aug 6:23:3808-3816.|Microchem J. 2025 Apr.|Microvasc Res. 2025 May 7:104816.|Mol Carcinog. 2024 Apr 17|Mol Carcinog. 2024 Jan;63 (1) :75-93.|Mol Ther. 2023 Feb 1;31 (2) :503-516.|Nat Biomed Eng. 2018 Aug;2 (8) :578-588.|Nucleic Acids Res. 2021 Jan 8;49 (D1) :D1113-D1121.|Oncogene. 2022 Mar;41 (12) :1821-1834.|Oncogene. 2024 May 17.|Oncotarget. 2016 Jul 19;7 (29) :45562-45574.|Oncotarget. 2017 Nov 15;8 (67) :111110-111118. |Patent. US20200276189A1.|Patent. US20220064117A1.|Patent. US20220288064A1.|Patent. US20230158019A1.|Patent. US20230226111A1.|Patent. US20240238271A1.|Patent. US20240325538A1.|PLoS One. 2024 Nov 1;19 (11) :e0308647.|Res Sq. 2025 Apr 14.|Research Square Preprint. 2021 May.|Sci Immunol. 2023 Mar 17;8 (81) :eade4656.|Sci Rep. 2025 Feb 8;15 (1) :4779.|Sci Rep. 2025 May 30;15 (1) :18978.|Sci Signal. 2019 Jul 16;12 (590) . pii: eaav7259.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Sensor Actuat B-Chem. 2021, 128991.|Signal Transduct Target Ther. 2023 Mar 1;8 (1) :90.|Stem Cell Reports. 2017 Dec 12;9 (6) :1948-1960.|Ther Adv Med Oncol. 2019 May 17:11:1758835919849757.|Theranostics. 2021 Jan 1;11 (6) :2691-2705.|Toxicol Lett. 2022 Jul 15:365:11-23.|Toxicol Lett. 2022 Jun 15:363:11-26.|Viruses. 2021 May 31;13 (6) :1035.|Adv Sci (Weinh) . 2024 Jul 2:e2402107.|Anticancer Drugs. 2014 Jul;25 (6) :673-82.|Biomed Chromatogr. 2019 Dec;33 (12) :e4674.|BMC Med. 2022 Aug 24;20 (1) :257|Bone Res. 2024 Apr 10;12 (1) :24.|Clin Cancer Res. 2025 May 1;31 (9) :1686-1699.|Harvard Medical School LINCS LIBRARY|J Bioenerg Biomembr. 2012 Feb;44 (1) :155-61.|J Chromatogr B Analyt Technol Biomed Life Sci. 2025 Apr 1:1255:124526.|J Pers Med. 2023 Jan 11;13 (1) :146.|Mol Cell Biochem. 2020 Jan;463 (1-2) :67-78|Nat Commun. 2025 Feb 14;16 (1) :1631.|Nat Commun. 2025 Jul 24;16 (1) :6777.|Nat Immunol. 2023 Sep;24 (9) :1443-1457.|Oncotarget. 2018 Apr 24;9 (31) :22158-22183. |Patent. US20220242943A1.|Pharmaceutics. 2023 Sep 12;15 (9) :2305.|Phytomedicine. 2024 Nov:134:155937.|PLoS Negl Trop Dis. 2019 Aug 20;13 (8) :e0007681. |PLoS One. 2017 Jun 1;12 (6) :e0178619.|Research Square Preprint. 2023 Nov 20.|University of Heidelberg. 2025.

• CAS Number :

  [152459-95-5]